ArticleSurgical endoscopy2026
Choledochoduodenostomy versus transpapillary stent by endoscopic retrograde cholangiopancreatography for preoperative biliary drainage before pancreatoduodenectomy: a French multicenter retrospective cohort study.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFew studies have compared the different types of endoscopic biliary drainage, particularly endoscopic retrograde cholangiopancreatography (ERCP) versus Endoscopic ultrasound guided-Choledochoduodenostomy (EUS-CD), for jaundice caused by malignant biliary obstruction prior to pancreatoduodenectomy.
methodsPatients were divided into two groups for biliary drainage: ERCP versus EUS-CD. Groups were compared in terms of post-procedure and postoperative morbidity and mortality rates. Overall survival (OS) and disease-free survival (DFS) rates were compared according to the type of BD in patients with pancreatic ductal adenocarcinoma (PDAC).
resultsBetween June 2016 and April 2023, 110 patients were included (EUS-CD, n = 32; ERCP, n = 78). There were no differences in terms of demographic characteristics, post-procedure morbidity, length of hospital stay, postoperative morbidity, and mortality after propensity score matching. Technical and clinical success rates were similar. Oncological safety did not differ between the groups. Soft pancreatic gland texture was the only factor influencing the occurrence of clinically relevant postoperative pancreatic fistula (p = 0.002). In the matched PDAC subgroup, extended resections were the only factor independently associated with overall survival (p = 0.015), whereas BD type (p = 0.020), patient sex (p = 0.032), and CA 19-9 levels (p = 0.032) were independently associated with disease-free survival. The ERCP group had numerically higher 1-, 3-, and 5-year OS rates than the EUS-CD group, without reaching statistical significance (p = 0.127). No significant difference in DFS was observed between groups (p = 0.694).
conclusionPostoperative morbidity and mortality were comparable between groups, with no significant differences observed in long-term survival outcomes.
Indexed as
Identifiers
42257926What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.